← back to search

Rhea N. Coler

Seattle University · US
Area of research
Infectious Diseases · Immunology
Research interest
Research interests include Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Research on Leishmaniasis Studies, and Immunotherapy and Immune Responses.
h-index
56
citations
14,032
works
192
NIH funding
primary concept
Medicine
email

Recent publications

Activity of a Three-Phage Combination against Mycobacterium Tuberculosis in Disease-Relevant Conditions
2026cited by 0position: contributordoi
Activity of a three-phage combination against <i>Mycobacterium tuberculosis</i> in disease-relevant conditions
2026cited by 0position: contributordoi
The Sm14+GLA-SE Recombinant Vaccine Against &lt;i&gt;Schistosoma mansoni&lt;/i&gt; and &lt;i&gt;S. haematobium&lt;/i&gt; in Adults and School Children: Phase II Clinical Trials in West Africa.
2025cited by 5position: contributordoi
Infant Antibodies After Maternal COVID-19 Vaccination During Pregnancy or Postpartum
PEDIATRICS 2025cited by 3position: middledoi
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent.
2025cited by 0position: contributordoi
Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk
Pathogens and Immunity 2025cited by 0position: contributordoi
Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals
Frontiers in Immunology 2024cited by 33position: middledoi
Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants
PEDIATRICS 2024cited by 27position: middledoi
Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.
2024cited by 4position: contributordoi
Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent
mSphere 2024cited by 1position: lastdoi
COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn
Vaccine 2023cited by 37position: middledoi
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
npj Vaccines 2023cited by 32position: middledoi
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
International Journal of Infectious Diseases 2023cited by 23position: contributordoi
Homologous and Heterologous Covid-19 Booster Vaccinations
New England Journal of Medicine 2022cited by 614position: middledoi
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Cell Reports Medicine 2022cited by 167position: middledoi
Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against <i>Mycobacterium avium</i> infection but is ineffective as an adjunct to antibiotic treatment in chronic disease.
2022cited by 8position: contributordoi
Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event
Tuberculosis 2022cited by 2position: contributordoi
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
2021cited by 29position: contributordoi
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
New England Journal of Medicine 2020cited by 3,477position: middledoi
Diagnostics and the neglected tropical diseases roadmap: setting the agenda for 2030
Transactions of the Royal Society of Tropical Medicine and Hygiene 2020cited by 72position: middledoi
The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.
2019cited by 111position: contributordoi
Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research
American Journal of Respiratory and Critical Care Medicine 2018cited by 64position: middledoi
Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis
Parasites & Vectors 2016cited by 50position: middledoi
Dissecting Mechanisms of Immunodominance to the Common Tuberculosis Antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ)
The Journal of Immunology 2012cited by 91position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 10 papers (2019–2026)S.E. Larsen · Infectious Disease Research Institute5 papers (2019–2026)Kathleen M. Neuzil · Meridian Clinical Research3 papers (2023–2025)Barbra A. Richardson · Eunice Kennedy Shriver National Institute of Child Health and Human Development2 papers (2023–2024)Marcela F. Pasetti · University of Maryland, Baltimore2 papers (2023–2024)Richard M. Novak · University of Illinois Chicago2 papers (2023–2024)Richard H. Beigi · The University of Texas Southwestern Medical Center2 papers (2023–2024)Bryan J. Berube · HDT Bio Corp.2 papers (2022–2025) · 2 papers (2026–2026)Saskia Janssen · Stellenbosch University2 papers (2026–2026)Susan L. Baldwin · Colorado State University2 papers (2021–2023)Katherine Bunge · National Institute of Allergy and Infectious Diseases2 papers (2023–2024)Cristina V. Cardemil · National Institutes of Health2 papers (2023–2024)Christine M. Posavad · Infectious Disease Research Institute2 papers (2023–2024)Flor M. Muñoz · Baylor College of Medicine2 papers (2023–2024)Mehul S. Suthar · Emory Healthcare2 papers (2023–2024)Rebecca C. Brady · Infectious Diseases Society of America2 papers (2023–2024)Lalitha Parameswaran · New York University2 papers (2023–2024)Martina L. Badell · Emory University2 papers (2023–2024)Courtney Olson‐Chen · University of Rochester Medical Center2 papers (2023–2024)